This announcement is a separate document:
江苏康缘药业股份有限公司监事会关于回购注销公司2022年度限制性股票激励计划部分已授予但尚未解除限售的限制性股票相关事项的核查意见
Inspection opinions of the board of supervisors of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on matters relating to the repurchase and cancellation of restricted stocks granted in part of the 2022 restricted stock incentive plan of the company but the sale
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated